Detailed explanation of the usage and dosage of trametinib, scientific medication is guaranteed!

Trametinib/Megenin (Trametinib) is a targeted therapy drug, mainly targeting BRAF mutant malignant tumors, such as malignant tumors caused by BRAF V600E or V600K mutations melanoma, thyroid cancer, non-small cell lung cancer and other cancers. The regimen of trametinib is usually determined based on the patient's specific condition and the type of tumor. During the treatment process, correct usage and dosage can not only ensure the efficacy of the drug, but also effectively reduce the occurrence of side effects.

For patients with BRAF mutation-positive malignant melanoma, the recommended dosage of trametinib is once daily, with the usual dose being 2 mg. If the patient experiences significant adverse reactions during medication, the doctor may adjust the dose based on the patient's tolerance. Treatment is often combined with dabrafenib to increase the effectiveness of the treatment. During combination therapy, the dose of trametinib is usually not adjusted and remains 2 mg once daily. During treatment, doctors will regularly check the patient's progress and adjust the dosage as needed.

For other BRAF mutation-positive tumor types, such as non-small cell lung cancer, the use of trametinib is similar, but the specific dose may be adjusted depending on the patient's constitution, tumor type and condition. Whether used as a single agent or in combination, patients should make dosage adjustments as recommended by their physician.

Trametinib needs to be taken orally on an empty stomach and the tablet should be swallowed whole without chewing or crushing the drug. In addition, patients may experience some minor side effects during treatment, such as rash, diarrhea, etc. Doctors usually adjust the treatment plan based on these reactions. During medication, regular liver and kidney function tests and cardiac function assessment are also very important to avoid potential toxic reactions.

Reference materials:https://go.drugbank.com/drugs/DB08911